21:56 , Feb 22, 2019 |  BioCentury  |  Politics, Policy & Law

Azar’s IPI: socialist or capitalist?

The Trump administration’s plan for an international reference pricing scheme for Medicare Part B drugs has provoked vituperative opposition from BIO, PhRMA and their allies who have branded it as an attempt to impose socialism....
04:45 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
19:35 , Feb 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Bone cancer; sarcoma; brain cancer Mouse studies suggest CAR T cells targeting B7-H3 could help treat pediatric osteosarcoma, Ewing sarcoma and brain cancer. In tumor samples from 388 patients with pediatric solid tumors and...
13:31 , Feb 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); melanoma Mouse studies suggest inhibiting CD95 could help enhance the efficacy of adoptive T cell therapies for melanoma and ALL. In a mouse model of melanoma, adoptive transfer of T...
02:06 , Feb 9, 2019 |  BioCentury  |  Politics, Policy & Law

Killing Part D rebates

HHS’s proposal to scrap the secret rebates drug manufacturers pay PBMs and health plans in Medicare Part D would help President Donald Trump fulfill promises to reduce drug prices. It would also reduce financial burdens...
00:53 , Feb 1, 2019 |  BC Innovations  |  Product R&D

BlueRock’s PD purity play

Regenerative medicine company BlueRock is gearing up to submit its first IND this year, banking on its approach to Parkinson’s disease to overcome the legacy of failed fetal transplants by offering a more stable and...
00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
23:51 , Jan 29, 2019 |  BC Extra  |  Politics & Policy

Senate to ‘compel’ pharma CEO testimony

Senate Finance Committee Chairman Chuck Grassley (R-Iowa) and ranking member Ron Wyden (D-Ore.) said at the start of a hearing Tuesday they will demand that pharma CEOs testify publicly about drug pricing after several companies...
20:49 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

Data presented at ASCO GI for Keytruda in esophageal cancers

Merck & Co. Inc. (NYSE:MRK) reported detailed data on Jan. 14 from the Phase III KEYNOTE-181 trial showing that Keytruda pembrolizumab monotherapy as second-line treatment for advanced or metastatic esophageal or esophagogastric junction carcinoma improved...
00:50 , Jan 15, 2019 |  BC Extra  |  Politics & Policy

MSKCC says senior execs may not hold industry board seats

Memorial Sloan Kettering Cancer Center has barred its senior executive officers from holding board positions at MSKCC spinouts or external for-profit health and science-related entities, according to a staff memo sent by SVP and Chief...